Jubilant Receives Favorable Rulings from the U.S. Patent Office Invalidating Bracco Rubidium-Infusion-System Patents YARDLEY, Pa., Feb. 17, 2020 (GLOBE NEWSWIRE) -- On February 7, 2020, Jubilant DraxImage Inc., and certain of its affiliates (“Jubilant”) were informed by the U.S. Patent Office that it agreed with...

Jubilant Radiopharma Receives Approval from Health Canada for Drax Exametazime® YARDLEY, Pa., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Jubilant Radiopharma, the Radiopharmaceutical Division of Jubilant Pharma Ltd, announced today that the company received approval from Health Canada...

Jubilant DraxImage receives approval for new pulmonary indications from the U.S. Food and Drug Administration for DRAXIMAGE® DTPA Montreal, QC, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a Jubilant Pharma wholly-owned subsidiary, is pleased to announce approval of new pulmonary indications for...

Jubilant DraxImage receives approval for 12-Hour shelf-life extension from the U.S. Food and Drug Administration for DRAXIMAGE® MAA Montreal, QC, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Jubilant DraxImage Inc. (“DraxImage”), a wholly-owned subsidiary of Jubilant Pharma, is pleased to announce the U.S. Food and Drug Administration...